Vmn2r116 Inhibitors
Vmn2r116 inhibitors pertain to a class of chemical compounds designed to selectively bind to and inhibit the activity of a specific receptor known as Vmn2r116. This receptor is part of a larger family of receptors known as vomeronasal type-2 receptors (V2Rs), which are typically expressed in the vomeronasal organ (VNO) of certain animals. V2Rs are G protein-coupled receptors (GPCRs) that are involved in the detection of pheromonal signals, playing a crucial role in intraspecies communication by mediating various social behaviors based on chemical signals. The Vmn2r116 receptor has a distinct structure that allows these inhibitors to bind with high affinity, which results in the modulation of the receptor's normal function. The design and development of Vmn2r116 inhibitors hinge on a profound understanding of the receptor's molecular structure, including the active sites and binding pockets where such compounds can exert their inhibitory effects.
The development of Vmn2r116 inhibitors is a complex task that involves a multi-step process, including the identification of the receptor's ligand-binding domain and the synthesis of molecules capable of interacting with this domain in a precise manner. This process often involves computational modeling and structure-activity relationship (SAR) studies to predict how different chemical modifications may impact the binding efficiency and specificity of the inhibitors. Once potential inhibitory compounds are identified, they undergo various analytical assays to determine their binding affinity, selectivity for the Vmn2r116 receptor, and their ability to alter the receptor's signaling pathway. These studies are essential to ascertain the efficacy of the inhibitors in relation to their target receptor without affecting other receptor subtypes or eliciting off-target effects. As these inhibitors are often small organic molecules, their synthesis must be carefully planned to ensure that they are not only effective but also stable under physiological conditions. This stability is crucial for the compounds to maintain their conformation and remain active for a sufficient duration to effectively interact with the Vmn2r116 receptor.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
(−)-Quinpirole hydrochloride | 85798-08-9 | sc-253339 | 10 mg | $141.00 | 1 | |
A dopamine receptor agonist that selectively binds to D2-like receptors. The activation of D2-like receptors can negatively regulate cyclic AMP (cAMP) levels, thereby potentially reducing the activation of downstream signaling pathways that could lead to the decreased functional activity of Vmn2r116. | ||||||
SCH 23390 | 125941-87-9 | sc-200408 sc-200408A | 5 mg 25 mg | $179.00 $733.00 | 2 | |
A dopamine D1 receptor antagonist that blocks the D1 receptor-mediated activation of adenylyl cyclase, subsequently leading to reduced cAMP levels and PKA activity, which may indirectly downregulate Vmn2r116 function if its activity is cAMP-dependent. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
An inhibitor of MEK, which is part of the MAPK/ERK pathway. Inhibition of this pathway can lead to altered gene expression profiles that may include the downregulation of Vmn2r116 if it is transcriptionally regulated by ERK signaling. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A PI3K inhibitor that blocks the PI3K/Akt signaling pathway. By inhibiting PI3K, this compound could prevent the phosphorylation and activation of downstream targets, potentially decreasing the functional activity of Vmn2r116 if it is regulated by PI3K/Akt signaling. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
A selective inhibitor of both MEK1 and MEK2. By preventing the activation of the ERK pathway, U0126 may reduce the transcription of certain genes, potentially including Vmn2r116 if its expression is controlled by ERK signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
A p38 MAPK inhibitor that can block the p38 signaling pathway, potentially leading to decreased expression or activity of Vmn2r116 if it is modulated by p38 MAPK-regulated transcription factors. | ||||||
L-NG-Nitroarginine Methyl Ester (L-NAME) | 51298-62-5 | sc-200333 sc-200333A sc-200333B | 1 g 5 g 25 g | $48.00 $107.00 $328.00 | 45 | |
A nitric oxide synthase inhibitor that reduces the production of nitric oxide, a signaling molecule that can modulate various biological processes, including neurotransmission and gene expression, potentially affecting the activity of Vmn2r116. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor that can suppress cell growth and proliferation. Inhibition of mTOR signaling may influence the expression or activity of Vmn2r116 if it is regulated by pathways involving mTOR. | ||||||
BAPTA/AM | 126150-97-8 | sc-202488 sc-202488A | 25 mg 100 mg | $138.00 $458.00 | 61 | |
A chelator of intracellular calcium that can prevent calcium-dependent signaling events. If Vmn2r116 is influenced by calcium signaling pathways, BAPTA-AM could indirectly reduce its activity. | ||||||
NF 449 | 389142-38-5 | sc-203159 | 10 mg | $314.00 | 5 | |
A potent and selective inhibitor of the purinergic receptor P2X1. If Vmn2r116 function is modulated by ATP signaling through P2X receptors, NF449 could indirectly inhibit its activity. | ||||||